查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球小儿神经母细胞瘤治疗市场
市场调查报告书
商品编码
1311898

2023-2030 年全球小儿神经母细胞瘤治疗市场

Global Pediatric Neuroblastoma Treatment Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 155 Pages | 商品交期: 2-3个工作天内

价格

全球小儿神经母细胞瘤治疗市场预计在预测期内将以 10.3% 的复合年增长率增长。小儿神经母细胞瘤治疗是指对影响儿童神经系统的癌症或肿瘤的一种治疗方法。预计在预测期内，小儿神经母细胞瘤新病例的增加将推动小儿神经母细胞瘤治疗市场的增长。例如，根据美国临床肿瘤学会（ASCO）发表的一篇文章，2023 年 3 月，美国每年约有 700 到 800 名青少年患上神经母细胞瘤。在美国，神经母细胞瘤占所有儿童恶性肿瘤的 6.0%。神经母细胞瘤影响约 90.0% 的五岁以下儿童。此外，政府加大研发投入，建设儿科医疗基础设施，也将进一步推动市场增长。例如，2022 年 3 月，拉力赛基金会向来自 31 个机构的 51 名研究人员提供了 340 万美元的资助，用于儿童癌症研究。

细分市场前景

全球小儿神经母细胞瘤治疗市场根据治疗类型和最终用户进行细分。根据治疗类型，市场被细分为化疗、免疫疗法、放射疗法和其他疗法。根据最终用户，市场细分为医院、专科诊所及其他。其中，医院细分市场将在全球小儿神经母细胞瘤治疗市场中占据突出的市场份额。这一增长得益于先进的治疗技术和多学科协作。

化疗细分市场有望占据全球儿科神经母细胞瘤治疗市场的主要份额

该细分市场增长的主要因素是化疗药物在治疗神经母细胞瘤方面的有效性。化疗是减轻症状和减少疾病扩散的首选治疗方法。化疗还可与放疗或手术等其他疗法结合使用。例如，2021年6月，纪念斯隆-凯特琳癌症中心（Memorial Sloan Kettering Cancer Center）赞助了一项临床研究，重点确定N9是否是治疗神经母细胞瘤患儿的一种安全有效的方法。环磷酰胺、托泊替康和长春新碱（CTV）这三种化疗药物组合构成了N9方案（CDV）。此外，对化疗治疗小儿神经母细胞瘤有效性的研究投入不断增加，将进一步推动该细分市场的增长。例如，2022 年 1 月，医学博士 Jason Shohet 获得了现代汽车希望基金提供的为期两年、价值 30 万美元的学者希望基金，用于克服神经母细胞瘤治疗中的耐药性。

地区展望

全球小儿神经母细胞瘤治疗市场根据地域进一步细分，包括北美（美国和加拿大）、欧洲（英国、意大利、西班牙、德国、法国及其他）、亚太地区（印度、中国、日本、韩国及其他）和世界其他地区（中东和非洲以及拉丁美洲）。其中，亚太地区预计将在预测期内以显著的复合年增长率增长，这主要是由于小儿神经母细胞瘤发病率的上升、精准医疗的进步以及医疗保健支出的增加等各种因素。

预计北美将占据全球小儿神经母细胞瘤治疗市场的重要份额

推动该地区市场增长的关键因素包括该地区小儿神经母细胞瘤的高发病率、完善的医疗基础设施以及新产品的批准。例如，2022 年 6 月，美国食品和药物管理局授予 Omblastys（omburtamab）生物制品许可申请优先审查权，用于治疗患有中枢神经系统或神经母细胞瘤脑膜转移（一种扩散到围绕大脑和脊髓的脑脊液的疾病）的儿童。

包括合作、合併和收购等在内的倡议不断增多，也将极大地促进市场的扩张。例如，2021 年 8 月，美国生物技术公司联合治疗公司（United Therapeutics）宣布与前 NFL 球员德文-斯蒂尔（Devon Still）及其女儿莉亚（Leah）合作，发起一项名为 "勇敢面对神经母细胞瘤"（Braving NeuroBLASToma）的教育倡议。该倡议旨在让人们更多地了解影响未成熟神经细胞（称为神经母细胞）的癌症。位于美国北卡罗来纳州的伊莎贝拉-桑托斯基金会（Isabella Santos Foundation）正在帮助那些孩子患有小儿神经母细胞瘤的人，为他们支付 1500.0 美元的精准医疗治疗费用。截至 2022 年 10 月，该基金会已帮助了约 81 名儿童，并打算在未来帮助更多儿童，直到保险支付精准医疗的费用。

目 录

第 1 章：报告摘要

  • 行业现状分析与增长潜力展望
  • 研究方法和工具
  • 市场细分
    • 按细分市场
    • 按地区

第 2 章：市场概述与洞察

  • 报告范围
  • 分析师洞察与当前市场趋势
    • 主要结论
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • APEIRON Biologics AG
    • 概述
    • 财务分析
    • SWOT 分析
    • 近期发展
  • Baxter Healthcare Corp.
    • 公司概况
    • 财务分析
    • SWOT 分析
    • 近期发展
  • Cellectar Biosciences, INC.
    • 概述
    • 财务分析
    • SWOT 分析
    • 近期发展
  • United Therapeutics Corp.
    • 概述
    • 财务分析
    • SWOT 分析
    • 近期发展
  • 关键战略分析

第四章：市场细分

  • 按治疗类型分類的全球小儿神经母细胞瘤治疗市场
    • 化疗
    • 免疫疗法
    • 放射治疗
    • 其他（手术、靶向治疗）
  • 按终端用户分類的全球小儿神经母细胞瘤治疗市场
    • 医院
    • 专科诊所
    • 其他（研究机构）

第 5 章 : 区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 意大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Cell Ectar Biosciences Inc.
  • Clarity Pharmaceuticals
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson Services, Inc.
  • MacroGenics Inc.
  • Marsala Biotech Inc.
  • Merck & Co.
  • Pfizer Inc.
  • Provectus Biopharmaceuticals Inc.
  • Sartorius AG
  • Sun Pharmaceuticals Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Y-mAbs Therapeutics Inc.
Product Code: OMR2027501

Title: Global Pediatric Neuroblastoma Treatment Market Size, Share & Trends Analysis Report by Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy, and Others), and by End-User (Hospitals, Specialty Clinics and Others) Forecast Period (2023-2030).

The global pediatric neuroblastoma treatment market is anticipated to grow at a CAGR of 10.3% during the forecast period. Pediatric neuroblastoma treatment refers to a kind of treatment for cancer or a tumor that affects the nervous system in children. The rising number of new cases of pediatric neuroblastoma is expected to propel the growth of the pediatric neuroblastoma treatment market over the forecast period. For instance, in March 2023, according to an article published by the American Society of Clinical Oncology (ASCO), a US-based organization for oncology professionals and physicians, neuroblastoma affects approximately 700 to 800 youngsters in the US each year. In the US, neuroblastoma accounts for 6.0% of all childhood malignancies. Neuroblastoma affects around 90.0% of children under the age of five. Additionally, the government's increased investments in R&D initiatives to build pediatric medical infrastructure will further boost market growth. For instance, in March 2022, Rally Foundation provides $3.4 million in grants to 51 researchers from 31 institutions for childhood cancer research.

Segmental Outlook

The global pediatric neuroblastoma treatment market is segmented based on treatment type and end-user. Based on treatment type, the market is sub-segmented into chemotherapy, immunotherapy, radiation therapy, and others. Based on the end-user, the market is sub-segmented into hospitals, specialty clinics, and others. Among these, the hospitals sub-segment to account for a prominent market share in the global pediatric neuroblastoma treatment market. The growth is attributed to the availability of advanced treatment technologies, and multidisciplinary collaboration.

The Chemotherapy Sub-Segment is Anticipated to Hold a Prominent Share of the Global Pediatric Neuroblastoma Treatment Market

The primary factor attributed to the sub-segment growth is the effectiveness of chemotherapeutic medications in the treatment of neuroblastoma. Chemotherapy is the preferred method of treatment to lessen symptoms and decrease the spread of the disease. It is also used in conjunction with other therapies like radiation therapy or surgery. For instance, in June 2021, the Memorial Sloan Kettering Cancer Center sponsored a clinical study that focused on determining whether N9 was a secure and efficient treatment for kids with neuroblastoma. Cyclophosphamide, topotecan, and vincristine (CTV) are the three chemotherapy drug combinations that make up the N9 regimen (CDV). Additionally, the increasing investments in researching the effectiveness of chemotherapy in treating pediatric neuroblastoma will further boost the sub-segment growth. For instance, in January 2022, Jason Shohet, MD, Ph.D., received a two-year $300,000 Scholar Hope Grant from Hyundai Hope on Wheels to focus on overcoming drug resistance in treatments for neuroblastoma.

Regional Outlook

The global pediatric neuroblastoma treatment market is further segmented based on geography including North America (the US and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East and Africa, and Latin America). Among these, the Asia-Pacific region is projected to expand at a significant CAGR during the forecast period, owing to various factors such as the increasing prevalence of pediatric neuroblastoma, advancements in precision medicine, and increasing healthcare expenditure.

North America is Anticipated to Hold a Significant Share of the Global Pediatric Neuroblastoma Treatment Market

Pivotal factors driving the market growth in the region include the high frequency of pediatric neuroblastoma in the region, the well-established healthcare infrastructure, and new product approvals. For instance, in June 2022, the FDA granted Omblastys (omburtamab) a priority review for a Biologics License Application for the treatment of children with the central nervous system or leptomeningeal metastasis (a disease that spreads to the cerebrospinal fluid that surrounds the brain and spinal cord) from neuroblastoma.

The growing initiatives including collaborations, mergers, and acquisitions, among others, will also significantly contribute to the market's expansion. For instance, in August 2021, United Therapeutics, an American biotechnology company, announced that it had partnered with former NFL player Devon Still and his daughter Leah to launch the educational initiative called 'Braving NeuroBLASToma'. The initiative intended to educate people more about cancer affecting immature nerve cells known as neuroblasts. The Isabella Santos Foundation based in North Carolina, US, is helping people whose children are suffering from pediatric neuroblastoma by paying $1500.0 for their treatment using precision medicine. The foundation helped around 81 kids by October 2022 and intends to help more in the future until insurance covers the cost of precision medicine.

Market Players Outlook

The major companies serving the global pediatric neuroblastoma treatment market include: APEIRON Biologics AG, Baxter Healthcare Corp., Cellectar Biosciences, Inc., and United Therapeutics Corp. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, funding, collaborations, and new product launches to stay competitive in the market. For instance, in March 2022, Recordati S.p.A., an Italy-based pharmaceutical group, acquired EUSA Pharma (UK) Ltd. for $824.2 million. The acquisition is expected to offer Recordati a broader portfolio of pharmaceuticals for rare diseases. EUSA Pharma (UK) Ltd. is a UK-based specialty pharmaceutical company that deals in pediatric neuroblastoma treatment.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global pediatric neuroblastoma treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. APEIRON Biologics AG
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Baxter Healthcare Corp.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Cellectar Biosciences, INC.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. United Therapeutics Corp.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Pediatric Neuroblastoma Treatment Market by Treatment Type
    • 4.1.1. Chemotherapy
    • 4.1.2. Immunotherapy
    • 4.1.3. Radiation Therapy
    • 4.1.4. Others (Surgery, Targeted Therapy)
  • 4.2. Global Pediatric Neuroblastoma Treatment Market by End-User
    • 4.2.1. Hospitals
    • 4.2.2. Specialty Clinics
    • 4.2.3. Others (Research Institutes)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. AstraZeneca
  • 6.2. Bayer AG
  • 6.3. Bristol-Myers Squibb Co.
  • 6.4. Cell Ectar Biosciences Inc.
  • 6.5. Clarity Pharmaceuticals
  • 6.6. Eli Lilly and Company
  • 6.7. F. Hoffmann-La Roche AG
  • 6.8. Johnson & Johnson Services, Inc.
  • 6.9. MacroGenics Inc.
  • 6.10. Marsala Biotech Inc.
  • 6.11. Merck & Co.
  • 6.12. Pfizer Inc.
  • 6.13. Provectus Biopharmaceuticals Inc.
  • 6.14. Sartorius AG
  • 6.15. Sun Pharmaceuticals Industries Ltd.
  • 6.16. Teva Pharmaceutical Industries Ltd.
  • 6.17. Y-mAbs Therapeutics Inc.

LIST OF TABLES

  • 1. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY CHEMOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY RADIATION THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY OTHER TREATMENT TYPES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 7. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT IN SPECIALTY CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT IN OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. NORTH AMERICAN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 12. NORTH AMERICAN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
  • 13. NORTH AMERICAN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 14. EUROPEAN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 15. EUROPEAN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
  • 16. EUROPEAN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 17. ASIA-PACIFIC PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 18. ASIA-PACIFIC PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
  • 19. ASIA-PACIFIC PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 20. REST OF THE WORLD PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. REST OF THE WORLD PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
  • 22. REST OF THE WORLD PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SHARE BY TREATMENT TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY CHEMOTHERAPY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY IMMUNOTHERAPY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY RADIATION THERAPY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY OTHER TREATMENT TYPES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SHARE BY END-USER, 2022 VS 2030 (%)
  • 7. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT IN HOSPITALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT IN SPECIALTY CLINICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT IN OTHER END-USERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. US PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 12. CANADA PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 13. UK PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 14. FRANCE PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 15. GERMANY PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. ITALY PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. SPAIN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. REST OF EUROPE PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. INDIA PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. CHINA PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. JAPAN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. SOUTH KOREA PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. REST OF ASIA-PACIFIC PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. REST OF THE WORLD PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)